Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedApr 14, 2026
DataAggregated Company Financials
Companies7
  • 7D1.9%
  • 3M-6.0%
  • 1Y1.0%
  • YTD-0.02%

In the last week, the Life Sciences industry is up 1.9%, with Lonza Group up 0.9%. Overall in the last year, the industry is flat. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 14 Apr 2026CHF 48.8bCHF 10.1bCHF 1.1b35.2x42.7x4.8x
Thu, 12 Mar 2026CHF 45.6bCHF 10.1bCHF 1.3b28x35.4x4.5x
Sat, 07 Feb 2026CHF 49.5bCHF 10.1bCHF 1.3b32.4x38.8x4.9x
Mon, 05 Jan 2026CHF 49.3bCHF 10.6bCHF 1.1b29.7x44.9x4.6x
Wed, 03 Dec 2025CHF 49.8bCHF 10.6bCHF 1.1b28.6x45.3x4.7x
Fri, 31 Oct 2025CHF 51.0bCHF 10.6bCHF 1.1b31.1x46.4x4.8x
Sun, 28 Sep 2025CHF 48.4bCHF 10.6bCHF 1.1b30.8x44x4.5x
Tue, 26 Aug 2025CHF 54.0bCHF 10.7bCHF 1.1b36x48.9x5.1x
Thu, 24 Jul 2025CHF 53.1bCHF 10.1bCHF 1.0b32.9x51.1x5.3x
Sat, 21 Jun 2025CHF 52.5bCHF 10.1bCHF 1.0b33.3x50.6x5.2x
Mon, 19 May 2025CHF 53.3bCHF 10.1bCHF 1.0b32.9x51.3x5.3x
Wed, 16 Apr 2025CHF 49.6bCHF 10.1bCHF 1.0b28.9x48.3x4.9x
Fri, 14 Mar 2025CHF 51.4bCHF 10.1bCHF 1.0b32.8x50.9x5.1x
Sun, 09 Feb 2025CHF 57.7bCHF 10.1bCHF 1.0b35.9x57.3x5.7x
Tue, 07 Jan 2025CHF 53.4bCHF 10.2bCHF 943.4m36.1x56.6x5.2x
Thu, 05 Dec 2024CHF 53.3bCHF 10.2bCHF 943.7m40.3x56.5x5.2x
Sat, 02 Nov 2024CHF 55.6bCHF 10.2bCHF 943.3m42.2x58.9x5.4x
Mon, 30 Sep 2024CHF 55.9bCHF 10.2bCHF 943.4m43.2x59.3x5.5x
Wed, 28 Aug 2024CHF 57.2bCHF 10.2bCHF 937.0m44.5x61x5.6x
Fri, 26 Jul 2024CHF 57.6bCHF 10.3bCHF 1.0b45.5x57.4x5.6x
Sun, 23 Jun 2024CHF 51.3bCHF 10.3bCHF 1.0b44.2x51.1x5x
Tue, 21 May 2024CHF 56.1bCHF 10.3bCHF 1.0b46x56x5.5x
Thu, 18 Apr 2024CHF 54.6bCHF 10.3bCHF 1.0b43.6x54.5x5.3x
Sat, 16 Mar 2024CHF 52.8bCHF 10.2bCHF 1.0b44.7x52.6x5.2x
Mon, 12 Feb 2024CHF 48.1bCHF 10.2bCHF 1.0b42.5x47.2x4.7x
Wed, 10 Jan 2024CHF 41.4bCHF 9.8bCHF 1.5b31.4x27.7x4.2x
Fri, 08 Dec 2023CHF 39.2bCHF 9.8bCHF 1.5b29.5x26.2x4x
Sun, 05 Nov 2023CHF 38.8bCHF 9.8bCHF 1.5b27.3x26x4x
Tue, 03 Oct 2023CHF 46.5bCHF 9.8bCHF 1.5b31.7x31.2x4.8x
Thu, 31 Aug 2023CHF 52.7bCHF 9.8bCHF 1.5b36.6x35.4x5.4x
Sat, 29 Jul 2023CHF 53.8bCHF 9.8bCHF 1.5b36.8x34.8x5.5x
Mon, 26 Jun 2023CHF 55.2bCHF 9.7bCHF 1.6b34.3x33.7x5.7x
Wed, 24 May 2023CHF 61.1bCHF 9.7bCHF 1.6b39.2x37.4x6.3x
Fri, 21 Apr 2023CHF 59.9bCHF 9.7bCHF 1.7b41.3x35.9x6.2x
Price to Earnings Ratio

35.9x


Total Market Cap: CHF 59.9bTotal Earnings: CHF 1.7bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.7x which is lower than its 3-year average PE of 46.0x.
  • The industry is trading close to its 3-year average PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 12% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.56%
Healthcare-0.28%
Life Sciences1.86%
Clinical Research and Equipment1.86%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 517.000.9%
+CHF 335.3m		-2.8%PE39.7x
BANB Bachem HoldingCHF 69.804.5%
+CHF 224.8m		46.8%PE35.2x
PPGN PolyPeptide GroupCHF 35.9020.5%
+CHF 201.3m		140.3%PS3.3x
SFZN Siegfried HoldingCHF 79.752.6%
+CHF 89.8m		-7.7%PE20.7x
SKAN SKAN GroupCHF 44.655.3%
+CHF 50.6m		-28.6%PE61.7x

Latest News

XLS
CHF 20.00
Xlife Sciences
7D
1.5%
1Y
4.2%
SKAN
CHF 44.65
SKAN Group
7D
5.3%
1Y
-28.6%

SKAN: Order Backlog And Dividend Outlook Will Support Future Upside Potential

Analysts have reduced their price target for SKAN Group from CHF 66.00 to CHF 62.50, citing updated assumptions that include a revised discount rate, fair value estimate, revenue growth outlook, profit margin expectations and future P/E multiple. What's in the News The Board of Directors plans to propose a dividend of CHF 0.22 per share for approval at the Annual General Meeting on May 7, 2026, corresponding to a 30% payout ratio (Key Developments).
TECN
CHF 134.50
Tecan Group
7D
-0.7%
1Y
-7.4%
SFZN
CHF 79.75
Siegfried Holding
7D
2.6%
1Y
-7.7%

SFZN: Lower Street Expectations Will Support Future Upside Potential

Analysts now see Siegfried's fair value aligning with a lower Street view, with a key price target reset to CHF 96 from CHF 108 as they highlight more balanced expectations following the recent downgrade. Analyst Commentary Recent Street commentary around Siegfried reflects a more cautious stance, with price targets reset and ratings adjusted to align expectations more closely with current execution and valuation risks.
LONN
CHF 517.00
Lonza Group
7D
0.9%
1Y
-2.8%

Lonza Group's (VTX:LONN) Solid Earnings Are Supported By Other Strong Factors

Apr 09
Lonza Group's (VTX:LONN) Solid Earnings Are Supported By Other Strong Factors
BANB
CHF 69.80
Bachem Holding
7D
4.5%
1Y
46.8%

BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential

Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.
PPGN
CHF 35.90
PolyPeptide Group
7D
20.5%
1Y
140.3%